{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:57:57Z","timestamp":1792292277131,"version":"4.4.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"7-8","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T00:00:00Z","timestamp":1628812800000},"content-version":"am","delay-in-days":408,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.bulcan.2020.04.016","type":"journal-article","created":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T21:21:43Z","timestamp":1592947303000},"page":"792-799","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Les carcinomes \u00e9pidermo\u00efdes m\u00e9tastatiques du canal anal \u00a0: prise en charge actuelle et perspectives"],"prefix":"10.1016","volume":"107","author":[{"given":"Ang\u00e9lique","family":"Saint","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovic","family":"Evesque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9ric","family":"Fran\u00e7ois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2020.04.016_bib0255","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.bulcan.2020.04.016_bib0260","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ijc.30716","article-title":"Worldwide burden of cancer attributable to HPV by site, country and HPV type","volume":"141","author":"De Martel","year":"2017","journal-title":"Int J Cancer"},{"key":"10.1016\/j.bulcan.2020.04.016_bib0265","first-page":"924","article-title":"International trends in anal cancer incidence rates","volume":"46","author":"Islami","year":"2017","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.bulcan.2020.04.016_bib0270","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0140-6736(96)03409-5","article-title":"Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research","volume":"348","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.bulcan.2020.04.016_bib0275","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1200\/JCO.1996.14.9.2527","article-title":"Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study","volume":"14","author":"Flam","year":"1996","journal-title":"JCO"},{"key":"10.1016\/j.bulcan.2020.04.016_bib0280","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1200\/JCO.1997.15.5.2040","volume":"15","author":"Bartelink","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2020.04.016_bib0285","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/sj.bjc.6605605","article-title":"Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I)","volume":"102","author":"Northover","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bulcan.2020.04.016_bib0290","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S1470-2045(13)70086-X","article-title":"Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2\u00d72\u00a0factorial trial","volume":"14","author":"James","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2020.04.016_bib0295","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s12029-015-9790-4","article-title":"Phase II Study of Capecitabine in Substitution of 5-FU in the Chemoradiotherapy Regimen for Patients with Localized Squamous Cell Carcinoma of the Anal Canal","volume":"47","author":"Oliveira","year":"2016","journal-title":"J Gastrointest Cancer"},{"key":"10.1016\/j.bulcan.2020.04.016_bib0300","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1007\/s10350-008-9361-x","article-title":"Abdominoperineal Resection for Anal Cancer","volume":"51","author":"Mariani","year":"2008","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.bulcan.2020.04.016_bib0305","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.1245\/s10434-012-2485-1","article-title":"Abdominoperineal resection for squamous cell anal carcinoma: survival and risk factors for recurrence","volume":"19","author":"Lef\u00e8vre","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.bulcan.2020.04.016_bib0310","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.ijrobp.2006.12.052","article-title":"Predictors and patterns of recurrence after definitive chemoradiation for anal cancer","volume":"68","author":"Das","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.bulcan.2020.04.016_bib0315","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1080\/07357900600815208","article-title":"Anal cancer: current and future methodology","volume":"24","author":"Eng","year":"2006","journal-title":"Cancer Investigation"},{"key":"10.1016\/j.bulcan.2020.04.016_bib0320","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.1200\/JCO.2012.43.8085","article-title":"Long-Term Update of US GI Intergroup RTOG 98-11\u00a0Phase III Trial for Anal Carcinoma: Survival, Relapse, and Colostomy Failure With Concurrent Chemoradiation Involving Fluorouracil\/Mitomycin Versus Fluorouracil\/Cisplatin","volume":"30","author":"Gunderson","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2020.04.016_bib0325","unstructured":"Cancer of the Anus, Anal Canal, and Anorectum - Cancer Stat Facts. SEER n.d. https:\/\/seer.cancer.gov\/statfacts\/html\/anus.html.(accessed October 2, 2019)."},{"key":"10.1016\/j.bulcan.2020.04.016_bib0330","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.radonc.2014.04.013","article-title":"Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"111","author":"Glynne-Jones","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.bulcan.2020.04.016_bib0335","doi-asserted-by":"crossref","first-page":"852","DOI":"10.6004\/jnccn.2018.0060","article-title":"Carcinoma, Version 2.2018, NCCN Clinical Practice Guidelines in OncologAnaly","volume":"16","author":"Benson","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.bulcan.2020.04.016_bib0340","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0002-9343(89)80702-8","article-title":"Combination of cisplatin plus fluoropyrimidine chemotherapy effective against liver metastases from carcinoma of the anal canal","volume":"87","author":"Ajani","year":"1989","journal-title":"Am J Med"},{"key":"10.1016\/j.bulcan.2020.04.016_bib0345","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3109\/02841869309083882","article-title":"Treatment of relapsing anal carcinoma","volume":"32","author":"Tanum","year":"1993","journal-title":"Acta Oncol"},{"key":"10.1016\/j.bulcan.2020.04.016_bib0350","first-page":"861","article-title":"5-fluorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer","volume":"86","author":"Faivre","year":"1999","journal-title":"Bull Cancer"},{"key":"10.1016\/j.bulcan.2020.04.016_bib0355","doi-asserted-by":"crossref","first-page":"11133","DOI":"10.18632\/oncotarget.2563","article-title":"The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal","volume":"5","author":"Eng","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.bulcan.2020.04.016_bib0360","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40487-016-0024-0","article-title":"Background and current treatment of squamous cell carcinoma of the anus","volume":"4","author":"Glynne-Jones","year":"2016","journal-title":"Oncol Ther"},{"key":"10.1016\/j.bulcan.2020.04.016_bib0365","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1634\/theoncologist.2016-0241","article-title":"Platinum-fluoropyrimidine and paclitaxel-based chemotherapy in the treatment of advanced anal cancer patients","volume":"22","author":"Sclafani","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.bulcan.2020.04.016_bib0370","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11912-018-0698-6","article-title":"Systemic therapies for advanced squamous cell anal cancer","volume":"20","author":"Sclafani","year":"2018","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.bulcan.2020.04.016_bib0375","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000361051","article-title":"Carboplatin and paclitaxel treatment is effective in advanced anal cancer","volume":"87","author":"Kim","year":"2014","journal-title":"Oncology"},{"key":"10.1016\/j.bulcan.2020.04.016_bib0380","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/1097-0142(20010801)92:3<642::AID-CNCR1365>3.0.CO;2-Z","article-title":"Paclitaxel, carboplatin, and long-term continuous infusion of 5-fluorouracil in the treatment of advanced squamous and other selected carcinomas: results of a Phase II trial","volume":"92","author":"Hainsworth","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.bulcan.2020.04.016_bib0385","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/annonc\/mdy424.022","volume":"29","author":"Rao","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2020.04.016_bib0390","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(18)30321-8","article-title":"Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2\u00a0study","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2020.04.016_bib0395","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.dld.2017.05.011","article-title":"Anal cancer: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SNFCP)","volume":"49","author":"Moureau-Zabotto","year":"2017","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.bulcan.2020.04.016_bib0400","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1097\/DCR.0000000000000827","article-title":"Multimodal therapy of squamous cell carcinoma of the anus with distant metastasis: a single-institution experience","volume":"60","author":"Evesque","year":"2017","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.bulcan.2020.04.016_bib0405","first-page":"4637","article-title":"Single-agent paclitaxel in advanced anal cancer after failure of cisplatin and 5-fluorouracil chemotherapy","volume":"31","author":"Abbas","year":"2011","journal-title":"Anticancer Res"},{"key":"10.1016\/j.bulcan.2020.04.016_bib0410","doi-asserted-by":"crossref","first-page":"6853","DOI":"10.1002\/cam4.2558","article-title":"Mitomycin and 5-fluorouracil for second-line treatment of metastatic squamous cell carcinomas of the anal canal","volume":"8","author":"Saint","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.bulcan.2020.04.016_bib0415","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1038\/bjc.2012.479","article-title":"EGFR and K-ras gene mutation status in squamous cell anal carcinoma: a role for concurrent radiation and EGFR inhibitors?","volume":"107","author":"Paliga","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bulcan.2020.04.016_bib0420","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1016\/j.humpath.2014.08.001","article-title":"No evidence of oncogenic KRAS mutations in squamous cell carcinomas of the anogenital tract and head and neck region independent of human papillomavirus and p16(INK4a) status","volume":"45","author":"Prigge","year":"2014","journal-title":"Hum Pathol"},{"key":"10.1016\/j.bulcan.2020.04.016_bib0425","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/apm.12306","article-title":"KRAS and BRAF mutations in anal carcinoma","volume":"123","author":"Serup-Hansen","year":"2015","journal-title":"APMIS"},{"key":"10.1016\/j.bulcan.2020.04.016_bib0430","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1097\/CAD.0000000000000383","article-title":"Epidermal growth factor receptor inhibition in metastatic anal cancer","volume":"27","author":"Rogers","year":"2016","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.bulcan.2020.04.016_bib0435","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1159\/000452766","article-title":"EGFR inhibitors in patients with advanced squamous cell anal carcinomas: a single-institution experience","volume":"92","author":"Kim","year":"2017","journal-title":"Oncology"},{"key":"10.1016\/j.bulcan.2020.04.016_bib0440","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/0092-8674(90)90409-8","article-title":"The E6\u00a0oncoprotein encoded by human papillomavirus types 16\u00a0and 18\u00a0promotes the degradation of p53","volume":"63","author":"Scheffner","year":"1990","journal-title":"Cell"},{"key":"10.1016\/j.bulcan.2020.04.016_bib0445","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1126\/science.2157286","article-title":"Association of human papillomavirus types 16\u00a0and 18\u00a0E6\u00a0proteins with p53","volume":"248","author":"Werness","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.bulcan.2020.04.016_bib0450","doi-asserted-by":"crossref","first-page":"9094","DOI":"10.1128\/MCB.23.24.9094-9103.2003","article-title":"Recapitulation of the effects of the human papillomavirus type 16\u00a0E7\u00a0oncogene on mouse epithelium by somatic Rb deletion and detection of pRb-independent effects of E7\u00a0in vivo","volume":"23","author":"Balsitis","year":"2003","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.bulcan.2020.04.016_bib0455","first-page":"636","article-title":"Frequent display of human papillomavirus type 16\u00a0E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter","volume":"63","author":"Welters","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.bulcan.2020.04.016_bib0460","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.1158\/0008-5472.CAN-04-0831","article-title":"Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2\u00a0and E6","volume":"64","author":"de Jong","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.bulcan.2020.04.016_bib0465","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/jso.23998","article-title":"Tumor-infiltrating CD8(+) T lymphocytes associated with clinical outcome in anal squamous cell carcinoma","volume":"112","author":"Hu","year":"2015","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.bulcan.2020.04.016_bib0470","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/bjc.2015.448","article-title":"Tumour-infiltrating lymphocyte scores effectively stratify outcomes over and above p16\u00a0post chemo-radiotherapy in anal cancer","volume":"114","author":"Gilbert","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bulcan.2020.04.016_bib0475","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1158\/2159-8290.CD-15-0563","article-title":"Adaptive immune resistance: how cancer protects from immune attack","volume":"5","author":"Ribas","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.bulcan.2020.04.016_bib0480","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S1470-2045(17)30104-3","article-title":"Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2\u00a0study","volume":"18","author":"Morris","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2020.04.016_bib0485","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/annonc\/mdx029","article-title":"Safety and antitumor activity of the anti-PD-1\u00a0antibody pembrolizumab in patients with recurrent carcinoma of the anal canal","volume":"28","author":"Ott","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2020.04.016_bib0490","article-title":"Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): results from the multicohort, phase II KEYNOTE-158\u00a0study","volume":"38","author":"Marabelle","year":"2020","journal-title":"JCO"},{"key":"10.1016\/j.bulcan.2020.04.016_bib0495","doi-asserted-by":"crossref","first-page":"852","DOI":"10.6004\/jnccn.2018.0060","article-title":"Anal Carcinoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology","volume":"16","author":"Benson","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.bulcan.2020.04.016_bib0250","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1001\/jamaoncol.2018.4051","article-title":"Combining immune checkpoint blockade and tumor-specific vaccine for patients with incurable human papillomavirus 16-related cancer: a phase 2\u00a0clinical trial","volume":"5","author":"Massarelli","year":"2019","journal-title":"JAMA Oncol"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455120302605?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455120302605?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:33:01Z","timestamp":1757791981000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455120302605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":50,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0007455120302605"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2020.04.016","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Les carcinomes \u00e9pidermo\u00efdes m\u00e9tastatiques du canal anal \u00a0: prise en charge actuelle et perspectives","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2020.04.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}